Singapore’s Coronavirus Bet Stumbles
Expensive jab likely not ready before the third quarter
The Singapore government, which last year was among Asia’s leaders in its efforts to combat the Covid-19 coronavirus, appears to have stumbled, after the Economic Development Board agreed to pay a San Diego-based biopharma company, Arcturus Therapeutics Holdings, Inc. US$220 million to develop a vaccine in conjunction with the Duke University-National U…
Keep reading with a 7-day free trial
Subscribe to Asia Sentinel to keep reading this post and get 7 days of free access to the full post archives.